ProMIS Neurosciences (PMN) Revenue & Revenue Breakdown
ProMIS Neurosciences Revenue Highlights
ProMIS Neurosciences Revenue by Period
ProMIS Neurosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | -100.00% |
| 2021-12-31 | $8.14K | 480.76% |
| 2020-12-31 | $1.40K | 52.30% |
| 2019-12-31 | $920.18 | 163.86% |
| 2018-12-31 | $348.74 | -95.57% |
| 2017-12-31 | $7.87K | 293.03% |
| 2016-12-31 | $2.00K | -86.06% |
| 2015-12-31 | $14.37K | -89.29% |
| 2014-03-31 | $134.18K | 175.72% |
| 2013-03-31 | $48.67K | -46.57% |
| 2012-03-31 | $91.09K | -92.60% |
| 2011-03-31 | $1.23M | 598.64% |
| 2010-03-31 | $176.16K | -9.02% |
| 2009-03-31 | $193.63K | -58.27% |
| 2008-03-31 | $464.02K | 110.99% |
| 2007-03-31 | $219.92K | 602.29% |
| 2006-03-31 | $31.31K | - |
ProMIS Neurosciences generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
ProMIS Neurosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $6.28K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $-4.17K | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | -100.00% |
| 2022-03-31 | $4.17K | 0.79% |
| 2021-12-31 | $4.14K | 3.51% |
| 2021-09-30 | $4.00K | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | -100.00% |
| 2020-12-31 | $222.51 | 100.00% |
| 2020-09-30 | - | -100.00% |
| 2020-06-30 | $1.15K | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $892.98 | 10645.85% |
| 2019-09-30 | $8.31 | -56.36% |
| 2019-06-30 | $19.04 | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $141.32 | -30.58% |
| 2018-09-30 | $203.56 | 100.00% |
| 2018-06-30 | - | -100.00% |
| 2018-03-31 | $3.87 | -94.97% |
| 2017-12-31 | $76.96 | -98.94% |
| 2017-09-30 | $7.26K | 100.00% |
| 2017-06-30 | - | -100.00% |
| 2017-03-31 | $493.41 | 343.59% |
| 2016-12-31 | $111.23 | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | -100.00% |
| 2016-03-31 | $1.92K | -496.06% |
| 2015-12-31 | $-483.56 | -108.44% |
| 2015-09-30 | $5.73K | 744.79% |
| 2015-06-30 | $678.32 | -92.46% |
| 2015-03-31 | $8.99K | -82.84% |
| 2014-09-30 | $52.39K | -58.77% |
| 2014-06-30 | $127.07K | 191.49% |
| 2014-03-31 | $43.59K | 30.42% |
| 2013-12-31 | $33.43K | 38.45% |
| 2013-09-30 | $24.14K | -29.36% |
| 2013-06-30 | $34.18K | 11.36% |
| 2013-03-31 | $30.69K | 97.64% |
| 2012-12-31 | $15.53K | 1857.06% |
| 2012-09-30 | $793.50 | -51.15% |
| 2012-06-30 | $1.62K | -21.83% |
| 2012-03-31 | $2.08K | -88.57% |
| 2011-12-31 | $18.17K | -52.22% |
| 2011-09-30 | $38.03K | 12.09% |
| 2011-06-30 | $33.93K | -46.63% |
| 2011-03-31 | $63.57K | 237.74% |
| 2010-12-31 | $18.82K | -98.24% |
| 2010-09-30 | $1.07M | 2500.91% |
| 2010-06-30 | $41.18K | 28.80% |
| 2010-03-31 | $31.97K | -53.10% |
| 2009-12-31 | $68.17K | 90.18% |
| 2009-09-30 | $35.85K | 0.80% |
| 2009-06-30 | $35.56K | -8.05% |
| 2009-03-31 | $38.67K | -13.17% |
| 2008-12-31 | $44.54K | -19.43% |
| 2008-09-30 | $55.29K | -25.82% |
| 2008-06-30 | $74.53K | -15.92% |
| 2008-03-31 | $88.64K | 73.99% |
| 2006-09-30 | $50.94K | 18.31% |
| 2006-06-30 | $43.06K | 2260.36% |
| 2005-09-30 | $1.82K | 219.26% |
| 2005-06-30 | $571.41 | - |
ProMIS Neurosciences generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
ProMIS Neurosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| STRO | Sutro Biopharma | $153.73M | $13.01M |
| FENC | Fennec Pharmaceuticals | $21.64M | $25.26M |
| IVA | Inventiva | $17.50M | $15.58M |
| NAMS | NewAmsterdam Pharma Company | $14.09M | $1.40M |
| CNTA | Centessa Pharmaceuticals | $6.88M | - |
| CUE | Cue Biopharma | $5.49M | $1.72M |
| OPT | Opthea | $108.41K | $61.27K |
| GANX | Gain Therapeutics | $55.18K | - |
| CGEM | Cullinan Oncology | - | - |
| BIVI | BioVie | - | - |
| INAB | IN8bio | - | - |
| PMN | ProMIS Neurosciences | - | - |
| HLVX | HilleVax | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| CMPX | Compass Therapeutics | - | - |
PMN Revenue FAQ
What is ProMIS Neurosciences’s yearly revenue?
ProMIS Neurosciences's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing a decrease of -100.00% compared to 2021. PMN's yearly revenue for 2021 was $8.14K, representing an increase of 480.76% compared to 2020.
What is ProMIS Neurosciences’s quarterly revenue?
ProMIS Neurosciences's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). PMN's quarterly revenue for Q4 2023 was $6.28K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is ProMIS Neurosciences’s revenue growth rate?
ProMIS Neurosciences's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.